Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples